Aziz Nazha, MD, Oncology, Cleveland, OH, UH Cleveland Medical Center

AzizNazhaMD

Oncology Cleveland, OH

Hematologic Oncology

Hematology and Medical Oncology Fellow

Dr. Nazha is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Nazha's full profile

Already have an account?

Education & Training

  • Cleveland Clinic FoundationFellowship, Hematology/Oncology, 2013 - 2016
  • University of Texas MD Anderson Cancer CenterFellowship, Leukemia Fellowship, 2011 - 2012
  • Atlantic City Medical CenterResidency, Internal Medicine, 2008 - 2011
  • University of Tichreen Faculty of MedicineClass of 2007

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2013 - 2022
  • TX State Medical License
    TX State Medical License 2011 - 2015
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Peskind Memorial Award for Excellence in Scientific Research Cleveland Clinic, 2016
  • AACR/ASCO Methods in Clinical Cancer Research Scholarship AACR/ASCO, 2016
  • Paul Calabresi Career Development Award (NIH K12) NIH, Case Comprehensive Cancer Center, 2016
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies  
    Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick..., Blood Cancer J, 1/31/2015
  • Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical and Therapeutic Implications  
    Nazha A, Khoury JD, Rampal R, Daver N, Oncologist, 1/24/2015
  • Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?  
    Nazha A, Sekeres MA, Gore SD, Zeidan AM, Oncologist, 1/20/2015
  • Join now to see all

Abstracts/Posters

  • FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in AdultsClinically Relevant Abstract
    Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features
    Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia
    Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • The Molecular Maelstrom of Myelodysplastic Syndromes (MDS) 
    60th American Society of Hematology Annual Meeting - 12/2/2018
  • Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Authored Content

  • ASH 2020 Study Preview: CBC Values as a Predicting Factor of Hypomethylating AgentsDecember 2020

Press Mentions

  • Virtual Workshop: Transforming the Practice of Mental Health Care
    Virtual Workshop: Transforming the Practice of Mental Health CareApril 24th, 2020
  • AI Opens Opportunities for Clinical Labs to Leverage Patient Data and Improve Diagnostic Accuracy
    AI Opens Opportunities for Clinical Labs to Leverage Patient Data and Improve Diagnostic AccuracyJune 10th, 2019
  • Nazha Discusses Ongoing Trials for Ruxolitinib-Refractory Patients with Myelofibrosis
    Nazha Discusses Ongoing Trials for Ruxolitinib-Refractory Patients with MyelofibrosisMay 30th, 2019
  • Join now to see all

Professional Memberships

Other Languages

  • Arabic

Hospital Affiliations